PTJ
VERV

Paul Tudor Jones’s Verve Therapeutics VERV Stock Holding History

Paul Tudor Jones’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-36,975
Closed -$169K – 3791
2025
Q1 		$169K Buy
+36,975
New +$248K ﹤0.01% 2894
2024
Q4 		– Sell
-41,544
Closed -$201K – 3539
2024
Q3 		$201K Sell
41,544
-1,105
-3% -$6.42K ﹤0.01% 2537
2024
Q2 		$208K Buy
42,649
+925
+2% +$5.81K ﹤0.01% 2151
2024
Q1 		$554K Buy
+41,724
New +$553K ﹤0.01% 1610
2023
Q4 		– Sell
-31,744
Closed -$421K – 2939
2023
Q3 		$421K Buy
31,744
+901
+3% +$14.5K ﹤0.01% 1761
2023
Q2 		$578K Sell
30,843
-8,931
-22% -$149K 0.01% 1630
2023
Q1 		$574K Buy
39,774
+13,489
+51% +$264K 0.01% 1537
2022
Q4 		$509K Buy
+26,285
New +$696K 0.01% 1570
2022
Q2 		– Sell
-24,216
Closed -$553K – 2538
2022
Q1 		$553K Buy
+24,216
New +$692K 0.01% 1217
2021
Q3 		– Sell
-7,904
Closed -$476K – 2823
2021
Q2 		$476K Buy
+7,904
New +$328K 0.01% 1192

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Paul Tudor Jones's VERV Position: Q2 2025 in Review

Paul Tudor Jones sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 36,975 shares — an estimated $169K sold.

Paul Tudor Jones first reported a position in VERV in Q2 2021 and held it in 10 quarters. The position peaked at $578K in Q2 2023. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Paul Tudor Jones reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Paul Tudor Jones sold 36,975 Verve Therapeutics shares in Q2 2025, an estimated $169K.
  • Paul Tudor Jones first reported a position in Verve Therapeutics in Q2 2021 and held it in 10 quarters.
  • Paul Tudor Jones's Verve Therapeutics position peaked at $578K in Q2 2023.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Tudor Investment Corp's 13F filing for Q2 2025, filed 14 Aug 2025.